Cantor Fitzgerald analyst Kristen Kluska initiated coverage of DBV Technologies (DBVT) with an Overweight rating and $42 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- Guggenheim starts DBV Technologies at Buy on peanut allergy market potential
- DBV Technologies initiated with a Buy at Guggenheim
- Optimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial Developments
- DBV Technologies announces last patient visit completed in VITESSE trial
- DBV Technologies appoints Kevin Trapp as chief commercial officer